@@@@Highlights •Relatively high proportion of PD-L1 expression in RET fusion-positve lung cancer.•RET fusion-positve patients with PD-L1 overexpression may benefit from chemoimmunotherapy.•Selective RET inhibitors displayed superior efficacy compared to cabozantinib.•KRAS mutation and EGFR amplification may mediates RET inhibitors resistance.